# Drug-drug Interaction Study Between UIC202304, and UIC202305

> **NCT07735052** · PHASE1 · COMPLETED · sponsor: **Korea United Pharm. Inc.** · enrollment: 40 (actual)

## Conditions studied

- Healhty

## Interventions

- **DRUG:** UIC202304 and co-administration of UIC202304 and UIC202305
- **DRUG:** UIC202305 and co-administration of UIC202304 and UIC202305

## Key facts

- **NCT ID:** NCT07735052
- **Lead sponsor:** Korea United Pharm. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-25
- **Primary completion:** 2023-11-24
- **Final completion:** 2024-09-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07735052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07735052, "Drug-drug Interaction Study Between UIC202304, and UIC202305". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07735052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*